144033-76-1

Upstream product

• 603042-05-3 C₁₇H₁₈O₅ 
• 2150-46-1 Methyl 2,5-dihydroxybenzoate 
• 94420-55-0 methyl 2-hydroxy-5-(tetrahydropyranyloxy)benzoate 
• 179749-30-5 2-Methoxymethoxy-5-(tetrahydro-pyran-2-yloxy)-benzoic acid methyl ester 

Downstream Products

• 51985-42-3 methyl 5-methoxy-2-(methoxymethyloxy)benzoate 
• 1244628-99-6 methyl 4-bromo-2,5-dihydroxybenzoate 
• 603042-05-3 C₁₇H₁₈O₅ 
• 179915-23-2 (1S,2R,6R)-1-(5-Methoxy-2-methoxymethoxy-benzyl)-2,6-dimethyl-2-((E)-4-methyl-penta-1,3-dienyl)-cyclohexanol 
• 179749-27-0 2-[(R)-2,6-Dimethyl-6-((E)-4-methyl-penta-1,3-dienyl)-cyclohex-1-enylmethyl]-4-methoxy-1-methoxymethoxy-benzene 
• 179749-15-6 2-Chloromethyl-4-methoxy-1-methoxymethoxy-benzene 
• 179749-31-6 (5-methoxy-2-(methoxymethoxy)phenyl)-methan-1-ol 

Relevant academic research and scientific papers

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS

The present invention provides compounds having formula (I), and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1 -R11, t, X, Y, Z, and n are as defined herein.

Total synthesis and absolute configuration of riccardiphenols A and B, isolated from the Liverwort Riccardia crassa

The title compounds were synthesized as optically active forms using chiral Michael addition of the imine, prepared from 2-methylcyclohexanone and (S)-(-)-phenylethylamine, to methyl propiolate. The etherification of the intermediate triol was accomplished by TsOH-catalyzed cyclization. The absolute configurations of the natural products, riccardiphenols A and B, were established as 1 and 2, respectively.